Menopausal Hormone Replacement Therapy
A recent comprehensive review of studies conducted in the 10 years since the GHI studies ceased provides the information needed to update recommendations for the use of HRT. The updated guidelines are likely to confirm current FDA recommendations suggesting that HRT is safe for short-term use at the lowest possible dose to alleviate severe menopausal symptoms. HRT is not recommended for long-term use or for the prevention of chronic conditions such as osteoporosis in menopausal women.
Hormone therapy is one of the state-approved treatments for relieving menopausal symptoms. These symptoms, caused by lower levels of estrogen during menopause, include hot flashes, sleep disturbances, and vaginal dryness. Today, doctors prescribe much lower doses for much shorter periods of time (3-5 years) than before 2002. Your age, family history, personal medical history, and severity of your menopausal symptoms are factors that can influence your decision to pursue hormone therapy. Talk to your healthcare provider about the benefits and risks of HTN, the different forms of HTN, and other alternative options. This analysis found that women who took estrogen after menopause had an increased risk of developing ovarian cancer.
Women who took combined hormone therapy had the same risk of lung cancer as women who took placebo. However, among those diagnosed with lung cancer, women who took estrogen plus progestin were more likely to die from the disease than those who took placebo. The GHI study found an increased annual risk of heart attacks of 7 per 10,000 women who took combination therapy, compared to women who took estrogen alone who did not see significant differences. The subsequent new analysis showed similar results for breast cancer and showed that there was no increased risk in the fifth decade, although the risk increased with age.
Menopause is a natural part of aging that usually develops over several years. An artificial state of menopause can occur after a woman has undergone a hysterectomy. This randomized clinical trial made headlines when it suggested that participants who received hormone replacement therapy had an increased risk of breast cancer with no health benefit to their heart. In several studies, the effects of postmenopausal hormones on ovarian cancer risk were inconsistent.
Hodis believes it could protect against uterine and possibly breast cancer. Participants in the “Advancing Postmenopausal Preventive Therapy” study include women aged 40 to 59 years within six years of menopause. The researchers will follow them for three Hormone Replacement Therapy Madison years and see if the drug reduces atherosclerosis and cognitive decline. Systemic and local treatment options for MHT are available in the United States. The choice a woman receives depends on the menopausal symptoms that the treatment must treat.
More than 5,000 women in the ET group took a daily dose of estrogen in the form of conjugated horse estrogen for an average of about 6 years. The researchers then followed them for several years to look for more effects of the hormone. Different types of studies can be used to investigate the cancer risk of hormone therapy during menopause. For those with cancer who have undergone treatments that affect their estrogen levels, BHRT has been shown to be effective in improving their overall well-being and quality of life. In one study, people with cancer who underwent BHRT found relief from treatment-related symptoms such as migraines, incontinence, low libido, and insomnia. The study also found that their breast cancer recurrence rate was no higher than average.
There is no one way to ensure the best possible quality of life around menopause and beyond. Every woman is unique and needs to weigh her discomfort against her fear of treatment. Risk is defined as the possibility or possibility of harm; It does not indicate that damage will occur. Overall, the risks of high blood pressure in younger women are lower than originally in all women aged 50 to 70 combined.
In the first study report, women who took combined hormone therapy had a lower risk of colorectal cancer than women who took placebo. However, colorectal tumors that occurred in the combined hormone therapy group were more advanced in detection than those in the placebo group. In addition, a follow-up study found that the reduced risk of colorectal cancer disappeared after study participants stopped taking combination hormone therapeutics.
For women who have had a hysterectomy, progestin does not need to be part of hormone therapy because there is no risk of endometrial cancer. Adding a progestin increases the risk of breast cancer, making it a better choice for women without a uterus. Women who took estrogen plus progestin were more likely to be diagnosed with breast cancer than women who took placebo.